Loading institutional data...
Loading institutional data...
Held by 353 of 5,944 reporting institutions (95th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.65B 100.0% | $5.00B 100.0% | $4.30B 100.0% | $3.94B 100.0% | $3.44B 100.0% | $3.03B 100.0% | $2.31B 100.0% | $1.94B 100.0% | $1.83B 100.0% | $935.6M 100.0% |
| Cost of Revenue | $4.56B 80.7% | $3.45B 69.0% | $2.81B 65.4% | $2.56B 65.0% | $2.66B 77.3% | $2.35B 77.5% | $1.80B 77.8% | $465.9M 24.0% | $547.9M 30.0% | $673.5M 72.0% |
| Gross Profit | $1.09B 19.3% | $1.01B 20.3% | $981.2M 22.8% | $866.9M 22.0% | $779.6M 22.7% | $682.3M 22.5% | $513.0M 22.2% | $422.2M 21.8% | $446.0M 24.4% | $262.1M 28.0% |
| Selling, General & Admin | $682.5M 12.1% | $630.3M 12.6% | $607.4M 14.1% | $566.1M 14.4% | $525.7M 15.3% | $500.2M 16.5% | $459.6M 19.9% | $345.9M 17.8% | $338.5M 18.5% | $38.8M 4.1% |
| Total Operating Expenses | $750.0M 13.3% | $691.2M 13.8% | $666.6M 15.5% | $626.7M 15.9% | $588.8M 17.1% | $571.5M 18.8% | $513.3M 22.2% | $383.9M 19.8% | $418.7M 22.9% | $273.1M 29.2% |
| Operating Income | $337.9M 6.0% | $321.8M 6.4% | $314.6M 7.3% | $240.2M 6.1% | $190.8M 5.5% | $110.8M 3.7% | -$319K -0.0% | $38.3M 2.0% | $27.3M 1.5% | -$11.0M -1.2% |
| Interest Expense | $54.6M 1.0% | $49.0M 1.0% | $51.2M 1.2% | $53.8M 1.4% | $67.0M 1.9% | $107.8M 3.6% | $73.7M 3.2% | $45.8M 2.4% | — | — |
| Other Income (Expense), net | -$55.0M -1.0% | -$38.2M -0.8% | $44.1M 1.0% | -$34.5M -0.9% | -$13.4M -0.4% | -$11.5M -0.4% | -$73.7M -3.2% | -$45.8M -2.4% | -$44.3M -2.4% | -$23.2M -2.5% |
| Pretax Income | $282.9M 5.0% | $283.6M 5.7% | $358.7M 8.3% | $205.8M 5.2% | $116.5M 3.4% | -$5.2M -0.2% | -$78.2M -3.4% | -$51.0M -2.6% | -$67.4M -3.7% | -$34.2M -3.7% |
| Income Tax Expense | $75.3M 1.3% | $71.8M 1.4% | $91.7M 2.1% | $55.2M 1.4% | -$23.4M -0.7% | $2.8M 0.1% | -$2.3M -0.1% | -$2.7M -0.1% | -$18.6M -1.0% | $2.0M 0.2% |
| Net Income | $207.6M 3.7% | $211.8M 4.2% | $267.1M 6.2% | $150.6M 3.8% | $139.9M 4.1% | -$8.1M -0.3% | -$75.9M -3.3% | -$6.1M -0.3% | $3.9M 0.2% | -$42.8M -4.6% |
| Per Share | ||||||||||
| EPS (Basic) | $1.28 | $1.23 | $1.49 | $0.83 | $0.78 | $-0.04 | $-0.49 | — | — | — |
| EPS (Diluted) | $1.27 | $1.23 | $1.48 | $0.83 | $0.77 | $-0.04 | $-0.49 | — | — | — |
| Weighted Avg Shares (Basic) | 162.1M | 171.6M | 179.0M | 181.1M | 179.9M | 181.0M | 156.3M | — | — | — |
| Weighted Avg Shares (Diluted) | 163.4M | 172.8M | 180.4M | 182.1M | 181.2M | 181.0M | 156.3M | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $24.50 today, the market must believe free cash flow compounds 5.6%/yr for a decade (off $278M normalized FCF).
The market's 5.6% is more conservative than its 8-yr track record.
2-stage DCF · 0.16B shares · net debt $928M
mean 114.1% · volatility σ 309% · implied rate exceeded in 4/7 yrs
Central path = implied 5.6%/yr growth; shaded band = ±1σ (309%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $310M buybacks = $310M returned on $217M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 8%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $233M covers the $7M due within a year 34.3× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~4.7% on $1.2B of debt.
Cash of $233M fully covers short-term debt of $7M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 14-yr range · 14th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 24.0 | 77.8 | 77.5 | 77.3 | 65.0 | 65.4 | 69.0 | 80.7 |
| Gross Profit | 21.8 | 22.2 | 22.5 | 22.7 | 22.0 | 22.8 | 20.3 | 19.3 |
| SG&A | 17.8 | 19.9 | 16.5 | 15.3 | 14.4 | 14.1 | 12.6 | 12.1 |
| Operating Income | 2.0 | -0.0 | 3.7 | 5.5 | 6.1 | 7.3 | 6.4 | 6.0 |
| Income Tax | -0.1 | -0.1 | 0.1 | -0.7 | 1.4 | 2.1 | 1.4 | 1.3 |
| Net Income | -0.3 | -3.3 | -0.3 | 4.1 | 3.8 | 6.2 | 4.2 | 3.7 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on OPCH: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| OPCH | $3.8B | 19.3× | 11.8× | 0.7× | 13.0% | 19.3% | 3.7% | 15.7% | 8.3% | 2.9× | 353 |
Peers = companies sharing OPCH's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.